Literature DB >> 23856329

Decreased cardiotrophin-1 levels are associated with a lower risk of developing the metabolic syndrome in overweight/obese children after a weight loss program.

Tara Rendo-Urteaga1, Sonia García-Calzón, Eduardo Martínez-Ansó, María Chueca, Mirentxu Oyarzabal, María Cristina Azcona-Sanjulián, Matilde Bustos, María Jesús Moreno-Aliaga, J Alfredo Martínez, Amelia Marti.   

Abstract

OBJECTIVE: Cardiotrophin-1 (CT-1) shares some similarities with other cytokines, and participates in the control of energy metabolism. Higher circulating levels are observed in obese humans, but little information is gathered in weight loss (WL) programs. Therefore, we aimed to investigate the association of serum CT-1 levels with metabolic variables and the risk of developing metabolic syndrome (MetS) after a WL program in overweight/obese children. SUBJECTS AND METHODS: Forty-four overweight/obese children (mean age 11.5 y; 50% males) undergoing a 10-week WL program were enrolled. Subjects were dichotomized at the median of Body Mass Index-Standard Deviation Score (BMI-SDS) change, as high and low responders after intervention.
RESULTS: CT-1 levels were significantly reduced (-48 fmol/mL, p=0.043) in the high responder group after the WL program. They had significantly lower body weight (-3.7 kg, p<0.001), body fat mass (-8%, p<0.001), BMI-SDS (-0.78, p<0.001) and waist circumference (-5.4 cm, p<0.001), and a significant improvement in lipid and glucose profiles (p<0.05). Interestingly, decreased CT-1 levels significantly predicted changes in total cholesterol (41%) and LDL-cholesterol (28%). Moreover, in our participants the lower the CT-1 levels, the higher the reduction in MetS risk components, after the 10-week intervention, (p-ANCOVA=0.040, p-trend=0.024).
CONCLUSION: We showed, for the first time, a reduction in serum CT-1 levels after a WL program and this decrease in CT-1 was strongly associated with a reduction in cholesterol levels and in MetS risk factors in overweight/obese children. Our findings may suggest that CT-1 could be an indirect marker for the diagnosis of MetS in this population.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BMI; BMI-SDS; Body Mass Index; Body Mass Index-Standard Deviation Score; CNTF; CT-1; Cardiotrophin-1; Child; Ciliary Neurotrophic Factor; Cytokine; HR; High Responder; IL-6; Interleukin-6; Intervention studies; LAP; LR; Lipid Accumulation Product; Low Responder; MetS; Metabolic Syndrome; Obesity; WC; WL; Waist Circumference; Weight loss

Mesh:

Substances:

Year:  2013        PMID: 23856329     DOI: 10.1016/j.metabol.2013.05.011

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  11 in total

Review 1.  Childhood obesity and the metabolic syndrome.

Authors:  Scott Owens; Riley Galloway
Journal:  Curr Atheroscler Rep       Date:  2014-09       Impact factor: 5.113

2.  Role of cardiotrophin-1 in the regulation of metabolic circadian rhythms and adipose core clock genes in mice and characterization of 24-h circulating CT-1 profiles in normal-weight and overweight/obese subjects.

Authors:  Miguel López-Yoldi; Kimber L Stanhope; Marta Garaulet; X Guoxia Chen; Beatriz Marcos-Gómez; María Paz Carrasco-Benso; Eva M Santa Maria; Xavier Escoté; Vivien Lee; Marinelle V Nunez; Valentina Medici; Eduardo Martínez-Ansó; Neira Sáinz; Ana E Huerta; Laura M Laiglesia; Jesús Prieto; J Alfredo Martínez; Matilde Bustos; Peter J Havel; Maria J Moreno-Aliaga
Journal:  FASEB J       Date:  2017-01-17       Impact factor: 5.191

3.  Total antioxidant capacity and oxidative stress after a 10-week dietary intervention program in obese children.

Authors:  T Rendo-Urteaga; B Puchau; M Chueca; M Oyarzabal; M C Azcona-Sanjulián; J A Martínez; A Marti
Journal:  Eur J Pediatr       Date:  2013-12-06       Impact factor: 3.183

Review 4.  Review: the Roles and Mechanisms of Glycoprotein 130 Cytokines in the Regulation of Adipocyte Biological Function.

Authors:  Dufang Ma; Yong Wang; Guofeng Zhou; Yongcheng Wang; Xiao Li
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

5.  Higher Lipopolysaccharide Binding Protein and Chemerin Concentrations Were Associated with Metabolic Syndrome Features in Pediatric Subjects with Abdominal Obesity during a Lifestyle Intervention.

Authors:  Amelia Marti; Isabel Martínez; Ana Ojeda-Rodríguez; María Cristina Azcona-Sanjulian
Journal:  Nutrients       Date:  2021-01-20       Impact factor: 5.717

6.  Cardiotrophin-1 is inversely associated with obesity in non-diabetic individuals.

Authors:  Hao-Chang Hung; Feng-Hwa Lu; Hung-Tsung Wu; Horng-Yih Ou; Yi-Ching Yang; Jin-Shang Wu; Chih-Jen Chang
Journal:  Sci Rep       Date:  2015-12-01       Impact factor: 4.379

Review 7.  Role of Omentin, Vaspin, Cardiotrophin-1, TWEAK and NOV/CCN3 in Obesity and Diabetes Development.

Authors:  Xavier Escoté; Saioa Gómez-Zorita; Miguel López-Yoldi; Iñaki Milton-Laskibar; Alfredo Fernández-Quintela; J Alfredo Martínez; María J Moreno-Aliaga; María P Portillo
Journal:  Int J Mol Sci       Date:  2017-08-15       Impact factor: 5.923

Review 8.  Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification-A Narrative Review.

Authors:  Alexander E Berezin; Alexander A Berezin
Journal:  Diabetes Ther       Date:  2020-05-19       Impact factor: 2.945

9.  Changes in objectively measured physical activity after a multidisciplinary lifestyle intervention in children with abdominal obesity: a randomized control trial.

Authors:  Lydia Morell-Azanza; Ana Ojeda-Rodríguez; Amaia Ochotorena-Elicegui; Nerea Martín-Calvo; María Chueca; Amelia Marti; Cristina Azcona-San Julian
Journal:  BMC Pediatr       Date:  2019-04-04       Impact factor: 2.125

10.  Plasma Cardiotrophin-1 as a Marker of Hypertension and Diabetes-Induced Target Organ Damage and Cardiovascular Risk.

Authors:  Luis Gamella-Pozuelo; Isabel Fuentes-Calvo; Manuel A Gómez-Marcos; José I Recio-Rodriguez; Cristina Agudo-Conde; José L Fernández-Martín; Jorge B Cannata-Andía; José M López-Novoa; Luis García-Ortiz; Carlos Martínez-Salgado
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.